1,067 results on '"Rampal, Raajit"'
Search Results
2. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
3. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
4. Biological drivers of clinical phenotype in myelofibrosis
5. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
6. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
7. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
8. Single-cell mutation analysis of clonal evolution in myeloid malignancies
9. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
10. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
11. Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.
12. Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.
13. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
14. Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
15. Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm
16. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
17. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
18. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
19. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression
20. Insights into the Pathobiology of Secondary AML
21. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
22. Can molecular insights guide treatment of AML evolved from MPNs?
23. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
24. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results
25. Interferons in the treatment of myeloproliferative neoplasms
26. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
27. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
28. Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease
29. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
30. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
31. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
32. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
33. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
34. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
35. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
36. Survival following allogeneic transplant in patients with myelofibrosis
37. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia
38. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor
39. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms
40. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
41. MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
42. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
43. Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies
44. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
45. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms*
46. Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes
47. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
48. Oral idasanutlin in patients with polycythemia vera
49. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
50. Insights into the Pathobiology of Secondary AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.